These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28091987)

  • 41. Survival and low-grade glioma: the emergence of genetic information.
    Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
    Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
    Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
    Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication.
    Fan Y; Peng X; Li B; Zhao G
    Biomed Res Int; 2020; 2020():1872962. PubMed ID: 32964017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
    Deng X; Lin D; Chen B; Zhang X; Xu X; Yang Z; Shen X; Yang L; Lu X; Sheng H; Yin B; Zhang N; Lin J
    Front Oncol; 2019; 9():1310. PubMed ID: 31824866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.
    Liu HQ; Li WX; An YW; Wu T; Jiang GY; Dong Y; Chen WX; Wang JC; Wang C; Song S
    Int J Immunopathol Pharmacol; 2022; 36():3946320221139262. PubMed ID: 36377597
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.
    Dekker LJM; Wu S; Jurriëns C; Mustafa DAN; Grevers F; Burgers PC; Sillevis Smitt PAE; Kros JM; Luider TM
    FASEB J; 2020 Mar; 34(3):3646-3657. PubMed ID: 31960518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.
    Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of Dysregulated microRNAs in Glioma Using RNA-sequencing.
    Liu C; Ge YY; Xie XX; Luo B; Shen N; Liao XS; Bi SQ; Xu T; Xiao SW; Zhang QM
    Curr Med Sci; 2021 Apr; 41(2):356-367. PubMed ID: 33877554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IDH-1R132H mutation status in diffuse glioma patients: implications for classification.
    Wang PF; Liu N; Song HW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2016 May; 7(21):31393-400. PubMed ID: 27120786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
    Zhang XQ; Kiang KM; Wang YC; Pu JK; Ho A; Cheng SY; Lee D; Zhang PD; Chen JJ; Lui WM; Fung CF; Leung GK
    J Neurooncol; 2015 Nov; 125(2):253-63. PubMed ID: 26337623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
    Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
    Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
    Vergara GA; Eugenio GC; Malheiros SMF; Victor EDS; Weinlich R
    J Neurooncol; 2020 May; 147(3):587-594. PubMed ID: 32222932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
    Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
    J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.